Modified recombinant human IgG1-Fc is superior to natural intravenous immunoglobulin at inhibiting immune-mediated demyelination. (2021)

First Author: Baksmeier C
Attributed to:  Core Support for Collaborative Research in Glycobiology funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/imm.13341

PubMed Identifier: 33880776

Publication URI: http://europepmc.org/abstract/MED/33880776

Type: Journal Article/Review

Volume: 164

Parent Publication: Immunology

Issue: 1

ISSN: 0019-2805